Are you Dr. Beaver?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 80 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
The Johns Hopkins Hospital
600 North Wolfe Street
Baltimore, MD 21287Phone+1 410-955-5000
Summary
- Dr. Julia Beaver, MD is an oncologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and District of Columbia. She is affiliated with Johns Hopkins Hospital.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013- Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Perelman School of Medicine at the University of PennsylvaniaClass of 2007
Certifications & Licensure
MD State Medical License 2010 - 2026
DC State Medical License 2013 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani
The Oncologist. 2024-08-05 - 1 citationsEvaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome.Daniall Masood, Luyao Ren, Cu Nguyen, Francesco G Brundu, Lily Zheng
Genome Biology. 2024-06-20 - 2 citationsFDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S Mishra-Kalyani, Yuan-Li Shen
Clinical Cancer Research. 2024-01-05
Press Mentions
Targeted Oncology - FDA Cracks down on Dangling Accelerated Approvals in 2021, Pathway Is ScrutinizedDecember 20th, 2021- FDA Posts New Websites on Accelerated Approvals for Cancer DrugsOctober 29th, 2021
- The FDA’s Accelerated Approval Process: When Drugs Are Cleared for Sale Based on Limited EvidenceOctober 18th, 2021
- Join now to see all
